Medium chain triglycerides and hepatic encephalopathy.
The oral administration of short (C(6)) and medium (C(8) and (C(10)) chain triglycerides produced no clinical or electroencephalographic changes in patients with cirrhosis of the liver. Arterial ammonia levels were also monitored in these patients and showed no significant change after medium chain triglycerides. It was concluded that medium chain triglycerides, known to be of potential value in the treatment of malabsorption in patients with cirrhosis, are not clinically contraindicated, even in patients with evidence of hepatic encephalopathy.
D000641:Ammonia / Q000097:blood; D002208:Caproates / Q000097:blood; D002746:Chlorpromazine; D004569:Electroencephalography; D005227:Fatty Acids / Q000097:blood / Q000134:cerebrospinal fluid; D006501:Hepatic Encephalopathy / Q000139:chemically induced*; D006801:Humans; D007408:Intestinal Absorption; D008103:Liver Cirrhosis / Q000188:drug therapy / Q000378:metabolism*; D014280:Triglycerides / Q000097:blood / Q000378:metabolism / Q000627:therapeutic use / Q000633:toxicity*
D002208:Caproates; D005227:Fatty Acids; D014280:Triglycerides; D000641:Ammonia; D002746:Chlorpromazine